Literature DB >> 28028009

Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2).

Alan S Maisel1, Salvatore Di Somma2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28028009     DOI: 10.1093/eurheartj/ehw462

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  4 in total

Review 1.  The Confounding Effects of Non-cardiac Pathologies on the Interpretation of Cardiac Biomarkers.

Authors:  Marin Nishimura; Alison Brann; Kay-Won Chang; Alan S Maisel
Journal:  Curr Heart Fail Rep       Date:  2018-08

Review 2.  Biomarker Development in Cardiology: Reviewing the Past to Inform the Future.

Authors:  Katharine A Kott; Michael Bishop; Christina H J Yang; Toby M Plasto; Daniel C Cheng; Adam I Kaplan; Louise Cullen; David S Celermajer; Peter J Meikle; Stephen T Vernon; Gemma A Figtree
Journal:  Cells       Date:  2022-02-08       Impact factor: 6.600

3.  The differential diagnostic value of selected cardiovascular biomarkers in Takotsubo syndrome.

Authors:  Albert Topf; Moritz Mirna; Vera Paar; Lukas J Motloch; Janine Grueninger; Christiane Dienhart; Paul C Schulze; Mathias C Brandt; Robert Larbig; Uta C Hoppe; Daniel Kretzschmar; Michael Lichtenauer
Journal:  Clin Res Cardiol       Date:  2021-11-02       Impact factor: 5.460

4.  Soluble ST2 as a Potential Biomarker for Risk Assessment of Pulmonary Hypertension in Patients Undergoing TAVR?

Authors:  Elke Boxhammer; Moritz Mirna; Laura Bäz; Nina Bacher; Albert Topf; Brigitte Sipos; Marcus Franz; Daniel Kretzschmar; Uta C Hoppe; Alexander Lauten; Michael Lichtenauer
Journal:  Life (Basel)       Date:  2022-03-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.